Skip to main content
. 2017 Oct 5;2(19):e89381. doi: 10.1172/jci.insight.89381

Figure 7. FR104 together with low-dose Treg cellular therapy prolongs human skin allograft survival.

Figure 7

(A) Mice received an adoptive transfer of 10 × 106 PBMCs together with a subtherapeutic dose of 1 × 106 ex vivo–expanded Tregs and were then treated with saline (n = 5), FR104 (n = 5), or CTLA4-Ig (n = 5) i.v. (B) FR104 together with the low-dose Treg cellular therapy promoted an extension in skin graft survival compared with subtherapeutic-dose Tregs alone (median of survival times [MST] = 89 vs. MST = 44, P = 0.0021, log-rank test). (C) Chimerism levels of human CD45+ cells in the peripheral blood on day 21 and day 28 after adoptive transfer.